ImmunoGen Appoints Blaine McKee as Executive Vice President and Chief Business Officer
“As ImmunoGen continues to evolve, we look to complement our existing
team with outside talent with experience to accelerate our transition to
a fully-integrated biotechnology company delivering innovative products
to improve outcomes for cancer patients,” said
Dr. McKee brings 25 years of experience in building biotechnology
companies and has extensive strategic, transactional, and market access
expertise. He joins ImmunoGen from
Dr. McKee currently serves on the Board of
“I am excited to join ImmunoGen during this transformational time,” said Dr. McKee. “The Company is well-positioned to realize its full potential by building on its leadership in ADCs with continued innovation in oncology. I look forward to working with the talented team at ImmunoGen to bring novel ADCs to market and make a meaningful difference in the lives of cancer patients.”
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. The Company’s lead product candidate, mirvetuximab soravtansine, is in the FORWARD I Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in the FORWARD II Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Transition Report on Form 10-K for the fiscal year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.
Sarah Kiely, 781-895-0600
Courtney O’Konek, 781-895-0600
FTI Consulting Inc.
Robert Stanislaro, 212-850-5657